Arno Therapeutics 10-Q 14 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 09, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	Arno Therapeutics, Inc
Entity Central Index Key	1,195,116
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ARNI
Entity Common Stock, Shares Outstanding		49,349,749

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 2,124,079	$ 66,988
Prepaid expenses and other current assets	203,354	260,694
Total current assets	2,327,433	327,682
Property and equipment, net	17,741	23,103
Security deposit	10,455	10,455
Total assets	2,355,629	361,240
Current liabilities
Accounts payable	1,065,320	1,010,215
Accrued expenses and other current liabilities	455,737	1,124,690
Convertible notes, net of financing costs of $10,091 at December 31, 2015	0	2,089,909
Capital lease obligation- short term	4,306	3,853
Deferred rent	2,084	1,910
Total current liabilities	1,527,447	4,230,577
Capital lease obligation- long term	782	4,070
Derivative liabilities	6,541,644	4,750,687
Total liabilities	8,069,873	8,985,334
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, $0.0001 par value, 35,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.0001 par value, 500,000,000 shares authorized, 47,849,036 and 20,408,616 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	8,213	5,469
Common stock subscribed (428,571 shares subscribed as of September 30, 2016)	150,000	0
Additional paid-in capital	97,122,946	84,665,390
Accumulated deficit	(102,995,403)	(93,294,953)
Total stockholders' deficit	(5,714,244)	(8,624,094)
Total liabilities and stockholders' deficit	$ 2,355,629	$ 361,240

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Unamortized Debt Issuance Expense		$ 10,091
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	35,000,000	35,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	47,849,036	20,408,616
Common stock, shares outstanding	47,849,036	20,408,616
Common Stock, Shares Subscribed but Unissued	428,571

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating expenses:
Research and development	$ 1,115,623	$ 1,792,758	$ 4,716,112	$ 6,915,408
General and administrative	1,115,644	1,082,031	3,650,975	3,800,865
Total operating expenses	2,231,267	2,874,789	8,367,087	10,716,273
Loss from operations	(2,231,267)	(2,874,789)	(8,367,087)	(10,716,273)
Other income/(expense):
Interest income	904	530	3,889	7,625
Interest expense	(214)	(349)	(14,982)	(1,139)
Other income/(expense), net	(1,618,438)	2,195,301	(1,322,270)	3,196,814
Total other income/(expense)	(1,617,748)	2,195,482	(1,333,363)	3,203,300
Net loss	$ (3,849,015)	$ (679,307)	$ (9,700,450)	$ (7,512,973)
Net loss per share - basic & diluted	$ (0.09)	$ (0.03)	$ (0.23)	$ (0.37)
Weighted-average shares outstanding- basic & diluted	44,705,825	20,408,616	41,691,545	20,408,616

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT - 9 months ended Sep. 30, 2016 - USD ($)	Total	PREFERRED STOCK	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	ACCUMULATED DEFICIT	Common Stock Subscribed [Member]
Balance at January 1, 2016 at Dec. 31, 2015	$ (8,624,094)	$ 0	$ 5,469	$ 84,665,390	$ (93,294,953)	$ 0
Balance at January 1, 2016 (in shares) at Dec. 31, 2015		0	20,408,616
Issuance of common shares upon conversion of note payable and accrued interest	2,128,652		$ 608	2,128,044
Issuance of common shares upon conversion of note payable and accrued interest (in shares)			6,081,858
Issuance of common shares pursuant to a stock purchase agreement, net of issuance costs	5,206,999		$ 1,507	5,205,492
Issuance of common shares pursuant to a stock purchase agreement, net of issuance costs (in shares)			15,072,139
Common stock and warrants sold in private placement, net of issuance costs	2,177,837		$ 629	2,177,208
Common stock and warrants sold in private placement, net of issuance costs (in shares)			6,286,423
Common shares subscribed	150,000					150,000
Net loss	(9,700,450)	$ 0	$ 0	0	(9,700,450)
Stock based compensation for services	2,946,812	0	0	2,946,812	0
Balance at September 30, 2016 at Sep. 30, 2016	$ (5,714,244)	$ 0	$ 8,213	$ 97,122,946	$ (102,995,403)	$ 150,000
Balance at September 30, 2016 (in shares) at Sep. 30, 2016		0	47,849,036

CONDENSED STATEMENT OF STOCKHO6

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (Parenthetical)	9 Months Ended
	Sep. 30, 2016USD ($)
Stock issuance costs	$ 68,251
Private Placement [Member]
Stock issuance costs	$ 22,413

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (9,700,450)	$ (7,512,973)
Adjustment to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation and amortization	5,362	5,822
Stock-based compensation	2,946,812	2,857,289
Change in fair value of derivative liability	1,790,957	(3,186,087)
Amortization of financing costs	10,091	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	57,340	6,876
Accounts payable	55,105	432,846
Accrued expenses	(640,301)	(426,833)
Deferred rent	174	341
Net cash used in operating activities	(5,474,910)	(7,822,719)
Cash flows from financing activities:
Payment of capital lease obligation	(2,835)	(2,445)
Proceeds from issuance of common stock and Series F warrants in private placement, net of issuance costs of $22,413	2,177,837	0
Proceeds from subscription of common stock	150,000	0
Proceeds from issuance of common stock, net of issuance costs of $68,251	5,206,999	0
Net cash provided by (used in) financing activities	7,532,001	(2,445)
Net increase (decrease) in cash and cash equivalents	2,057,091	(7,825,164)
Cash and cash equivalents at beginning of period	66,988	7,948,436
Cash and cash equivalents at end of period	2,124,079	123,272
Supplemental schedule of cash flows information:
Cash paid for interest	748	1,139
Supplemental schedule of non-cash investing and financing activities:
Conversion of notes payable to common stock	2,100,000	0
Conversion of accrued interest to common stock	$ 28,652	$ 0

CONDENSED STATEMENTS OF CASH F8

CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Stock Issuance Costs	$ 68,251	$ 0
Payments of Stock Issuance Costs	$ 22,413	$ 0

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2016
Business Combination, Description [Abstract]
DESCRIPTION OF BUSINESS	1. DESCRIPTION OF BUSINESS Arno Therapeutics, Inc. (“Arno” or the “Company”) is developing innovative drug candidates intended to treat patients with cancer and other life threatening diseases. The Company was incorporated in Delaware in March 2000, at which time its name was Laurier International, Inc. (“Laurier”). Pursuant to an Agreement and Plan of Merger dated March 6, 2008 (as amended, the “Merger Agreement”), by and among the Company, Arno Therapeutics, Inc., a Delaware corporation formed on August 1, 2005 (“Old Arno”), and Laurier Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Laurier Acquisition”), on June 3, 2008, Laurier Acquisition merged with and into Old Arno, with Old Arno remaining as the surviving corporation and a wholly-owned subsidiary of Laurier. Immediately following this merger, Old Arno merged with and into Laurier and Laurier’s name was changed to Arno Therapeutics, Inc. These two merger transactions are hereinafter collectively referred to as the “Merger.” Immediately following the Merger, the former stockholders of Old Arno collectively held 95

BASIS OF PRESENTATION AND SUMMA

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company has not yet generated any revenue from the sale of products and, through September 30, 2016, its efforts have been principally devoted to developing its licensed technologies and raising capital. The Company has experienced negative cash flows from operating activities since its inception and has an accumulated deficit of approximately $ 103.0 The accompanying unaudited Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q adopted under the Securities Exchange Act of 1934, as amended. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of Arno’s management, the accompanying Condensed Financial Statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. The interim results for the periods ended September 30, 2016 are not necessarily indicative of results for the full 2016 fiscal year or any other future interim periods. These unaudited Condensed Financial Statements have been prepared by management and should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission. The preparation of financial statements in conformity with generally accepted accounting principles requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates and assumptions principally relate to services performed by third parties but not yet invoiced, estimates of the fair value and forfeiture rates of stock options issued to employees and consultants, and estimates of the probability in the fair value of derivative liabilities. Actual results could differ from those estimates. Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated office, insurance, depreciation, and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the study and the invoices received from its external service providers. The Company adjusts its accruals when actual costs become known. Costs related to the acquisition of technology rights for which development work is still in process are charged to operations as incurred and considered a component of research and development expense. The Company accounts for the warrants issued in connection with the 2013, 2012 and 2010 Purchase Agreements (see Note 8) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-01, “Financial Instruments” (“ASU 2016-01”). Equity investments not accounted for under the equity method of accounting will be measured at fair value, with changes in fair value recognized in current earnings. ASU 2016-01 becomes effective for fiscal years beginning after December 15, 2017. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this standard will have a material impact on its financial statements, results of operations or related financial statement disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Leasees will need to recognize virtually all of their leases on the balance sheet, by recording a right-of-use asset and lease liability. ASU 2016-02 becomes effective for the Company on January 1, 2019, and early adoption is permitted upon issuance. The Company is evaluating the potential impact of adopting this standard on its financial statements. In March 2016, the FASB issued two updates to Derivatives and Hedging (Topic 815). Accounting Standards Update No. 2016-05, “Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships” (“ASU 2016-05”). ASU 2016-05 clarifies that a change in the counterparty to a derivative instrument that has been designated as a hedging instrument does not, on its own, require dedesignation of that hedge accounting relationship provided that all other hedge accounting criteria continue to be met. Accounting Standards Update No. 2016-06, “Contingent Put and Call Options in Debt Instruments” (“ASU 2016-06”). ASU 2016-06 clarifies that an entity is required to assess the embedded call or put option solely in accordance with a specific four-step decision sequence and are not also required to assess whether the contingency for exercising the option is indexed to interest rate or credit risk. ASU 2016-05 and ASU 2016-06 will take effect for public companies in fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company does not believe the requirements of these updates will have a material effect in the presentation of its financial statements. In March 2016, the FASB issued an update to Compensation- Stock Compensation (Topic 718). Accounting Standards Update No. 2016-09, “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). ASU 2016-09 identifies areas for simplification involving several aspects of accounting for stock-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. ASU 2016-09 is effective for reporting periods beginning after December 31, 2016. Early adoption is permitted. The Company is evaluating the potential impact of adopting this standard on its financial statements. In August 2016, the FASB issued an update to Statement of Cash Flows (Topic 230). Accounting Standards Update No. 2016-15, “Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). ASU 2016-15 provides guidance in the presentation and classification of eight specific cash flow issues in the statement of cash flows. ASU 2016-15 will take effect for public companies in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the potential impact of adopting this standard on its financial statements.

LIQUIDITY AND CAPITAL RESOURCES

LIQUIDITY AND CAPITAL RESOURCES	9 Months Ended
	Sep. 30, 2016
Working Capital Information [Abstract]
LIQUIDITY AND CAPITAL RESOURCES	3. LIQUIDITY AND CAPITAL RESOURCES Cash resources as of September 30, 2016 were approximately $ 2.1 0.1 3.0 The long-term success of the Company depends on its ability to develop new products to the point of regulatory approval and subsequent revenue generation and, accordingly, to raise enough capital to finance these developmental efforts. Management plans to raise additional capital either by selling shares of its stock or other securities, issuing additional indebtedness or by licensing the rights to one or more of its product candidates to finance the continued operating and capital requirements of the Company. Amounts raised will be used to further develop the Company’s product candidates, acquire rights to additional product candidates and for other working capital purposes. While the Company will extend its best efforts to raise additional capital to fund all operations into January, 2017 and beyond, management can provide no assurances that the Company will be successful in raising sufficient funds. If the Company is not successful, it may be required to discontinue its operations. In addition, to the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates, or grant licenses on terms that may not be favorable to the Company. Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments that might result from the in ability of the Company to continue as a going concern.

BASIC AND DILUTED INCOME_(LOSS)

BASIC AND DILUTED INCOME/(LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2016
Earnings Per Share, Basic and Diluted [Abstract]
BASIC AND DILUTED INCOME/(LOSS) PER SHARE	4. BASIC AND DILUTED INCOME/(LOSS) PER SHARE Basic net loss per share is calculated by dividing the loss available to common shareholders by weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated similarly to basic loss per share except that the denominator is based on the weighted-average number of shares of common stock and other dilutive securities outstanding during the period. The potential dilutive shares of common stock resulting from the assumed exercise of stock options and warrants are determined under the treasury stock method. As of September 30, 2016 and 2015, potentially dilutive securities include: Nine Months Ended September 30, 2016 2015 Warrants to purchase common stock 7,598,439 4,455,231 Options to purchase common stock 4,154,304 - Total potentially dilutive securities 11,752,743 4,455,231 For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net loss per share as their effect is anti-dilutive. In addition to the potentially dilutive securities, the aggregate number of common equivalent shares (related to options and warrants) that have been excluded from the computations of diluted loss per common share at September 30, 2016 and 2015 were 56,585,279 30,707,113

INTANGIBLE ASSETS AND INTELLECT

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	5. INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY License Agreements Onapristone License Agreement The Company’s rights to onapristone are governed by a license agreement with Invivis Pharmaceuticals, Inc. (“Invivis”), dated February 13, 2012. Under this agreement, the Company holds an exclusive, royalty-bearing license for the rights to commercialize onapristone for all therapeutic uses. The license agreement provides the Company with worldwide rights to develop and commercialize onapristone with the exception of the commercialization rights in France; provided that the Company has an option to acquire French commercial rights from Invivis upon notice to Invivis together with additional consideration. The onapristone license agreement provides the Company with exclusive, worldwide rights to a United States provisional patent application that relates to assays for predictive biomarkers for anti-progestin efficacy. The Company intends to expand its patent portfolio by filing additional patent applications covering the use of onapristone, the manufacture of onapristone and/or a companion diagnostic product. If the pending patent application issues, the issued patent would be scheduled to expire in 2031. The Company made a one-time cash payment of $ 500,000 February 13, 2012 15.1 150,000 100,000 350,000 70,833 50,000 Under the license agreement with Invivis, the Company also agreed to indemnify and hold Invivis and its affiliates harmless from any and all claims arising out of or in connection with the production, manufacture, sale, use, lease, consumption or advertisement of onapristone, provided, however, that the Company shall have no obligation to indemnify Invivis for claims that (a) any patent rights infringe third party intellectual property, (b) arise out of the gross negligence or willful misconduct of Invivis, or (c) result from a breach of any representation, warranty confidentiality obligation of Invivis under the license agreement. The license agreement will terminate upon the later of (i) the last to expire valid claim contained in the patent rights, and (ii) February 13, 2032. In general, Invivis may terminate the license agreement at any time upon a material breach by the Company to the extent the Company fails to cure any such breach within 90 90 University of Minnesota License In February 2014, we entered into an Exclusive Patent License Agreement with the Regents of the University of Minnesota, or “UM”, pursuant to which we were granted an exclusive, worldwide, royalty-bearing license for the rights to develop and commercialize technology embodied by certain patent applications relating to a gene expression signature derived from archived breast cancer tissue samples. We plan to develop and commercialize this technology as part of our companion diagnostic development program as a tool to identify progesterone-stimulated pathway activation, which in turn may identify patients who would be more likely to benefit from treatment with onapristone. The license agreement requires us to use commercially reasonable efforts to commercialize the licensed technology as soon as practicable, and includes several performance milestones relating to the development and commercialization of the technology to be achieved by us at specified dates. Under the terms of the agreement, we made a small one-time cash payment and reimbursed UM for past patent expenses it has incurred. The agreement also provides that we will pay royalties to UM on net sales of “Licensed Products” (as defined in the agreement) at a rate in the low-single digits, which royalty obligation terminates on a licensed product-by-licensed product and country-by-country basis upon the first date when there is no longer a valid claim under a licensed patent or patent application covering such licensed product in the country where the licensed product is made or sold. The term of the license agreement continues until the last date on which there is any active licensed patent or pending patent application. UM may terminate the agreement earlier upon a breach by us of one or more of our obligations that remains uncured for a period specified in the agreement. UM may also terminate the agreement if we voluntarily file for bankruptcy or similar proceeding, or if a petition for an involuntary bankruptcy proceeding is filed and is not released for 60 90 The license agreement further provides that we will indemnify and hold UM and its affiliates harmless from any and all suits, actions, claims, liabilities, demands, damages, losses or expenses relating to our exercise of its rights under the agreement, including our right to commercialize the licensed technology. UM is required to indemnify us with respect to claims relating to or resulting from its breach of the agreement. AR-12 and AR-42 License Agreements The Company’s rights to both AR-12 and AR-42 are governed by separate license agreements with The Ohio State University Research Foundation (“Ohio State”) entered into in January 2008. Pursuant to each of these agreements, Ohio State granted the Company exclusive, worldwide, royalty-bearing licenses to commercialize certain patent applications, know-how and improvements relating to AR-12 and AR-42 for all therapeutic uses. Under our license agreement for AR-12, we have exclusive, worldwide rights to seven issued U.S. patent and three pending U.S. patent applications that relate to AR-12, AR-12 analogs, and particular uses of AR-12 according to our business plan. On July 9, 2015, the Company and The Ohio State Innovation Foundation (formerly, The Ohio State Research Foundation) (“Ohio State”) entered into an amendment, dated effective as of May 15, 2015 (the “Amendment”), to the parties’ License Agreement dated January 3, 2008 (the “AR-12 License”), pursuant to which the Company was granted an exclusive license to certain patents and other technology relating to its AR-12 product candidate. The purpose of the Amendment was to clarify the scope of AR-12 analogs covered by the license grant in the original AR-12 License. In addition, the Amendment provides the Company with a first option to an exclusive license to patents and other technology relating to compounds related to AR-12 held by Ohio State. The issued patents include composition of matter claims. The issued patents are currently scheduled to expire in 2024. If the pending patent applications issue, the latest of the issued patent or patents would be scheduled to expire in 2034. In 2014, we filed a provisional patent application directed to methods using AR-12 that, if issued, would expire in 2035. In addition, Arno has exclusive rights to a pending US and international patent application directed to AR-12 formulations which, if issued, would expire in 2034. Under our license agreement for AR-42, we have exclusive, worldwide rights to one issued and two pending U.S. patent applications that relate to AR-42 and particular uses of AR-42 according to our business plan. If one of the pending patent applications issues, the issued patent or patents would be scheduled to expire in 2024. If the other pending patent application issues, it would be scheduled to expire in 2034. In 2008, pursuant to our license agreements for AR-12 and AR-42, we made one-time cash payments to Ohio State in the aggregate amount of $ 450,000 6.1 5.0 5.1 4.0 The license agreements with Ohio State further provide that we will indemnify Ohio State from any and all claims arising out of the death of or injury to any person or persons or out of any damage to property, or resulting from the production, manufacture, sale, use, lease, consumption or advertisement of either AR-12 or AR-42, except to the extent that any such claim arises out of the gross negligence or willful misconduct of Ohio State. The license agreements for AR-12 and AR-42, respectively, expire on the later of (i) the expiration of the last valid claim contained in any licensed patent and (ii) 20 90 90 AR-67 License Agreement During the nine months ended September 30, 2016, the Company sold to a third party for approximately $ 500,000

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Sep. 30, 2016
Convertible Notes Payable [Abstract]
CONVERTIBLE NOTES PAYABLE	6. CONVERTIBLE NOTES PAYABLE On October 21, 2015, the Company issued a series of 6 2,100,000 October 21, 2016 3,500,000 2,100,000 6 12,528 On January 12, 2016, in connection with the Company’s entry into the January 2016 Purchase Agreement (See Note 8) the $ 2,100,000 28,652 6,081,858 0.35 10,091

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	7. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company defines fair value as the amount at which an asset (or liability) could be bought (or incurred) or sold (or settled) in a current transaction between willing parties, that is, other than in a forced or liquidation sale. The fair value estimates presented in the table below are based on information available to the Company as of September 30, 2016. The accounting standard regarding fair value measurements discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: · Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. · Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. · Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. Quoted Market Prices in Active Significant Other Observable Significant Other Unobservable Markets Inputs Inputs Fair Value September 30, 2016 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2012 Series A $ 2,079,948 $ - $ - $ 2,079,948 Warrant liability - 2012 placement agent 3,689 - - 3,689 Warrant liability - 2013 Series D 4,454,068 - - 4,454,068 Warrant liability - 2013 placement agent 3,939 - - 3,939 Total $ 6,541,644 $ - $ - $ 6,541,644 Quoted Market Prices in Active Significant Other Observable Significant Other Unobservable Markets Inputs Inputs Fair Value December 31, 2015 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2012 Series A $ 1,753,969 $ - $ - $ 1,753,969 Warrant liability - 2012 placement agent 7,661 - - 7,661 Warrant liability - 2013 Series D 2,985,512 - - 2,985,512 Warrant liability - 2013 placement agent 3,545 - - 3,545 Total $ 4,750,687 $ - $ - $ 4,750,687 Fair Value Measurement Using Significant Unobservable Inputs (Level 3) Total 2013 2012 Warrant 2013 2013 Placement 2012 2012 Placement 2010 Liability Series E Series D Agent Series B Series A Agent Class B Balance at January 1, 2015 $ 6,671,524 $ 25,737 $ 3,011,249 $ 18,907 $ 12,381 $ 3,507,938 $ 67,246 $ 28,066 Total gains or losses: Unrealized appreciation/(depreciation) (1,920,837) (25,737) (25,737) (15,362) (12,381) (1,753,969) (59,585) (28,066) Balance at December 31, 2015 $ 4,750,687 $ - $ 2,985,512 $ 3,545 $ - $ 1,753,969 $ 7,661 $ - Total gains or losses: Unrealized appreciation/(depreciation) 1,790,957 1,468,556 394 325,979 (3,972) Balance at September 30, 2016 $ 6,541,644 $ - $ 4,454,068 $ 3,939 $ - $ 2,079,948 $ 3,689 $ - Value per Warrant $ 0.132 $ - $ 0.157 $ 0.060 $ - $ 0.099 $ 0.013 $ -

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2016
Stockholders Equity Note [Abstract]
STOCKHOLDERS' EQUITY	8. STOCKHOLDERS’ EQUITY Common Stock As of September 30, 2016, the Company had 47,849,036 68,338,022 On January 12, 2016, the Company entered into a Stock Purchase Agreement (the “January 2016 Purchase Agreement”) with certain purchasers identified therein (the “Purchasers”) pursuant to which the Company agreed to sell, and the Purchasers agreed to purchase, an aggregate of 21,153,997 0.35 7.4 2,128,652 6,081,858 6 On August 15, 2016, the Company entered into a Securities Purchase Agreement (the “August 2016 Purchase Agreement”) with certain purchasers pursuant to which it agreed to issue and sell in a private placement 8,501,421 0.35 0.4375 6,286,423 2.2 285,714 100,000 150,000 1,929,284 675,250 1,214,999 425,250 714,285 250,000 Warrants In accordance with the 2010 sale and issuance of Series A preferred stock, the Company issued two-and-one-half-year “Class A” warrants to purchase an aggregate of 152,740 8.00 801,885 9.20 3.55 0.0 152,740 801,885 Pursuant to the 2012 Purchase Agreement for the sale and issuance of 8% Senior Convertible Debentures, the Company issued five-year Series A Common Stock Purchase Warrants (The “Series A Warrants”) to purchase an aggregate of approximately 6,190,500 shares of common stock at an initial exercise price of $4.00 per share and 18-month Series B Common Stock Purchase Warrants (The “Series B Warrants” and together with the Series A Warrant, the “2012 Warrants”) to purchase an aggregate of approximately 6,190,500 2.40 12 2.40 10,317,464 1.36 18,207,273 1.18 21,009,562 2.1 1.8 6,190,500 In connection with the sale of the Debentures and 2012 Warrants, the Company engaged Maxim Group LLC, or Maxim, to serve as placement agent. In consideration for its services, the Company paid Maxim a placement fee of $ 1,035,000 7,500 five 283,750 2.64 0.0 Under the terms of the 2013 Purchase Agreement for the issuance and sale of common stock, each Purchaser received Series D Common Stock Purchase Warrant (a “Series D Warrant”) and a Series E Common Stock Warrant (a “Series E Warrant” and together with the Series D Warrant, the “2013 Warrants”)) and had the option to elect to receive a Series C Common Stock Purchase Warrant (a “Series C Warrant”) in lieu of a share in connection with each unit it purchased. The Series C Warrants have a five-year term and are exercisable at an initial exercise price of $ 0.01 2.40 4.00 2.14 12,868,585 24,053,398 1.81 28,369,815 4.5 3.0 12,868,585 Pursuant to the terms of the August 2016 Purchase Agreement for the issuance and sale of common stock, the Company issued Series F Warrants to purchase an aggregate of approximately 3,145,208 0.4375 Description Grant Date Warrants Issued Exercise Weighted Average Expiration Exercised Warrants 2012 Series A 11/26/2012 17,966,139 $ 1.1786 $ 1.1786 11/26/2017 - 17,966,139 2012 Placement 11/26/2012 261,250 $ 2.6400 $ 2.6400 11/26/2017 - 261,250 2012 Series A 12/18/2012 3,043,423 $ 1.1786 $ 1.1786 12/18/2017 - 3,043,423 2012 Placement 12/18/2012 22,500 $ 2.6400 $ 2.6400 12/18/2017 - 22,500 2013 Series C 10/29/2013 4,455,231 $ 0.0100 $ 0.0100 10/29/2018 - 4,455,231 2013 Series D 10/29/2013 28,369,815 $ 1.8144 $ 1.8144 10/29/2018 - 28,369,815 2013 Placement 10/29/2013 65,650 $ 2.6400 $ 2.6400 10/29/2018 - 65,650 2016 Series F 08/15/2016 3,143,208 $ 0.4375 $ 0.4375 08/15/2021 - 3,143,208 57,327,216 $ 1.37 - 57,327,216

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
STOCK BASED COMPENSATION	9. STOCK BASED COMPENSATION The Company’s 2005 Stock Option Plan (the “2005 Plan”) was originally adopted by the Board of Directors of Old Arno in August 2005, and was assumed by the Company on June 3, 2008 in connection with the Merger. After giving effect to the Merger, there were initially 373,831 875,000 945,276 945,276 11,155,295 The 2005 Plan is administered by the Board, or a committee appointed by the Board, which determines recipients and types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. The term of stock options granted under the 2005 Plan cannot exceed 10 The 2005 Plan expired on March 31, 2016 with 7,018,549 On March 14, 2016, the Board of the Company adopted the Company’s 2016 Equity Incentive Plan (the “2016 Plan”). The 2016 Plan replaces the Company’s 2005 Plan. Incentives under the 2016 Plan may be granted in any one or a combination of the following forms: (a) incentive stock options and non-statutory stock options, (b) stock appreciation rights, (c) stock awards, (d) restricted stock and (e) performance shares. The stock to be awarded or optioned under the 2016 Plan will consist of authorized but unissued or reacquired shares of common stock. The maximum aggregate number of shares of common stock reserved and available for awards under the 2016 Plan is 9,000,000 Any employee, director, or consultant may participate in the 2016 Plan; provided, however, that only employees are eligible to receive incentive stock options. Additionally, the Company may grant certain performance-based awards to “covered employees” in compliance with Section 162(m) of the Internal Revenue Code. These covered employees include our executive officers. No person may be granted options, stock appreciation rights, restricted stock awards, restricted stock units or performance awards under the 2016 Plan for more than 4,000,000 The term of stock options granted under the 2016 Plan cannot exceed 10 As of September 30, 2016, there are 5,007,743 Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Research and development $ 220,960 $ 275,429 $ 703,324 $ 830,180 General and administrative 804,487 658,900 2,243,488 2,027,109 Total $ 1,025,447 $ 934,329 $ 2,946,812 $ 2,857,289 The Company grants stock options to employees and members of the Board of Directors with the exercise prices equal to the closing price of the underlying shares of the Company’s common stock on the date that the options are granted. Options granted have a term of 10 In addition during the nine months ended September 30, 2016 the Company granted stock options to members of senior management that contain certain conditions to the exercisability of the shares subject thereto (“Contingent Options”) with the exercise prices equal to the closing price of the underlying shares of the Company’s common stock on the date that the options are granted. The Contingent Options granted have a term of 10 Three Months Ended Nine Months Ended 2016 2015 2016 2015 Stock Options - - 2,459,799 - Contingent Options - - 1,621,106 - Total granted - - 4,080,905 - Three Months Ended Nine Months Ended 2016 2015 2016 2015 Expected volatility N/A N/A 82% - 85% N/A Expected term N/A N/A 6 years N/A Dividend yield N/A N/A 0.0% N/A Risk- free interest rate N/A N/A 1.14% - 1.55% N/A Stock price N/A N/A $0.30 - $0.37 N/A Forfeiture rate N/A N/A 0.0% N/A A summary of the status of the options issued under the Company’s equity incentive plans at September 30, 2016, and information with respect to the changes in options outstanding, is as follows: Number of Weighted- Aggregate Options outstanding at December 31, 2015 7,027,658 $ 2.57 $ 7,824 Granted 4,080,905 0.37 414,296 Exercised - - - Cancelled (97,757) 2.23 - Options outstanding at September 30, 2016 11,010,806 $ 1.76 $ 422,120 Options vested and expected to vest at September 30, 2016 11,010,806 $ 1.76 $ 422,120 Exercisable at September 30, 2016 6,658,434 $ 2.53 $ 30,677 Shares available for grant under the 2016 Plan 5,007,743 Outstanding Exercisable Exercise Price Number of Weighted- Weighted- Number Weighted- $ 0.30 88,648 9.28 $ 0.30 19,699 $ 0.30 $ 0.36 48,399 9.09 $ 0.36 13,444 $ 0.36 $ 0.37 4,017,257 9.52 $ 0.37 258,496 $ 0.37 $ 0.85 136,785 8.09 $ 0.85 79,791 $ 0.85 $ 1.30 100,000 8.02 $ 1.30 59,375 $ 1.30 $ 2.40 5,097,075 6.46 $ 2.40 4,852,574 $ 2.40 $ 2.90 1,420,259 7.32 $ 2.90 1,272,672 $ 2.90 $ 8.00 65,000 3.82 $ 8.00 65,000 $ 8.00 $ 19.38 37,383 1.53 $ 19.38 37,383 $ 19.38 Total 11,010,806 7.72 $ 1.76 6,658,434 $ 2.53 The grant date fair value of options vested under the Company’s equity incentive plans was approximately $ 952,576 935,446 2,802,664 3,590,708 At September 30, 2016, total unrecognized estimated compensation cost related to stock options granted prior to that date was approximately $ 1,784,552 2.5

SUBSEQUENT EVENT

SUBSEQUENT EVENT	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	10. SUBSEQUENT EVENTS As described above under “Note 8, Stockholders’ Equity - Common Stock,” on October 4, 2016, the Company closed on the sale of an additional 285,714 142,857 100,000 1,929,284 675,250 The registration statement covering such shares and warrant shares was declared effective on November 3, 2016 by the Securities and Exchange Commission. The Company closed on the sale of 1,214,999 425,250 714,285 250,000

BASIS OF PRESENTATION AND SUM19

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Research and Development	Research and Development Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated office, insurance, depreciation, and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the study and the invoices received from its external service providers. The Company adjusts its accruals when actual costs become known. Costs related to the acquisition of technology rights for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.
Warrant Liability	Warrant Liability The Company accounts for the warrants issued in connection with the 2013, 2012 and 2010 Purchase Agreements (see Note 8) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error.
Recently Issued Accounting Pronouncements	Recent Accounting Pronouncements In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-01, “Financial Instruments” (“ASU 2016-01”). Equity investments not accounted for under the equity method of accounting will be measured at fair value, with changes in fair value recognized in current earnings. ASU 2016-01 becomes effective for fiscal years beginning after December 15, 2017. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this standard will have a material impact on its financial statements, results of operations or related financial statement disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Leasees will need to recognize virtually all of their leases on the balance sheet, by recording a right-of-use asset and lease liability. ASU 2016-02 becomes effective for the Company on January 1, 2019, and early adoption is permitted upon issuance. The Company is evaluating the potential impact of adopting this standard on its financial statements. In March 2016, the FASB issued two updates to Derivatives and Hedging (Topic 815). Accounting Standards Update No. 2016-05, “Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships” (“ASU 2016-05”). ASU 2016-05 clarifies that a change in the counterparty to a derivative instrument that has been designated as a hedging instrument does not, on its own, require dedesignation of that hedge accounting relationship provided that all other hedge accounting criteria continue to be met. Accounting Standards Update No. 2016-06, “Contingent Put and Call Options in Debt Instruments” (“ASU 2016-06”). ASU 2016-06 clarifies that an entity is required to assess the embedded call or put option solely in accordance with a specific four-step decision sequence and are not also required to assess whether the contingency for exercising the option is indexed to interest rate or credit risk. ASU 2016-05 and ASU 2016-06 will take effect for public companies in fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company does not believe the requirements of these updates will have a material effect in the presentation of its financial statements. In March 2016, the FASB issued an update to Compensation- Stock Compensation (Topic 718). Accounting Standards Update No. 2016-09, “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). ASU 2016-09 identifies areas for simplification involving several aspects of accounting for stock-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. ASU 2016-09 is effective for reporting periods beginning after December 31, 2016. Early adoption is permitted. The Company is evaluating the potential impact of adopting this standard on its financial statements. In August 2016, the FASB issued an update to Statement of Cash Flows (Topic 230). Accounting Standards Update No. 2016-15, “Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). ASU 2016-15 provides guidance in the presentation and classification of eight specific cash flow issues in the statement of cash flows. ASU 2016-15 will take effect for public companies in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the potential impact of adopting this standard on its financial statements.

BASIC AND DILUTED INCOME_(LOS20

BASIC AND DILUTED INCOME/(LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share, Basic and Diluted [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	As of September 30, 2016 and 2015, potentially dilutive securities include: Nine Months Ended September 30, 2016 2015 Warrants to purchase common stock 7,598,439 4,455,231 Options to purchase common stock 4,154,304 - Total potentially dilutive securities 11,752,743 4,455,231

FAIR VALUE OF FINANCIAL INSTR21

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis	The Company has determined the fair value of certain liabilities using the market approach. The following table presents the Company’s fair value hierarchy for these liabilities measured at fair value on a recurring basis as of September 30, 2016: Quoted Market Prices in Active Significant Other Observable Significant Other Unobservable Markets Inputs Inputs Fair Value September 30, 2016 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2012 Series A $ 2,079,948 $ - $ - $ 2,079,948 Warrant liability - 2012 placement agent 3,689 - - 3,689 Warrant liability - 2013 Series D 4,454,068 - - 4,454,068 Warrant liability - 2013 placement agent 3,939 - - 3,939 Total $ 6,541,644 $ - $ - $ 6,541,644 Quoted Market Prices in Active Significant Other Observable Significant Other Unobservable Markets Inputs Inputs Fair Value December 31, 2015 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2012 Series A $ 1,753,969 $ - $ - $ 1,753,969 Warrant liability - 2012 placement agent 7,661 - - 7,661 Warrant liability - 2013 Series D 2,985,512 - - 2,985,512 Warrant liability - 2013 placement agent 3,545 - - 3,545 Total $ 4,750,687 $ - $ - $ 4,750,687
Summary of Changes in Fair Value of Liabilities	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized depreciation that relate to those liabilities held at September 30, 2016: Fair Value Measurement Using Significant Unobservable Inputs (Level 3) Total 2013 2012 Warrant 2013 2013 Placement 2012 2012 Placement 2010 Liability Series E Series D Agent Series B Series A Agent Class B Balance at January 1, 2015 $ 6,671,524 $ 25,737 $ 3,011,249 $ 18,907 $ 12,381 $ 3,507,938 $ 67,246 $ 28,066 Total gains or losses: Unrealized appreciation/(depreciation) (1,920,837) (25,737) (25,737) (15,362) (12,381) (1,753,969) (59,585) (28,066) Balance at December 31, 2015 $ 4,750,687 $ - $ 2,985,512 $ 3,545 $ - $ 1,753,969 $ 7,661 $ - Total gains or losses: Unrealized appreciation/(depreciation) 1,790,957 1,468,556 394 325,979 (3,972) Balance at September 30, 2016 $ 6,541,644 $ - $ 4,454,068 $ 3,939 $ - $ 2,079,948 $ 3,689 $ - Value per Warrant $ 0.132 $ - $ 0.157 $ 0.060 $ - $ 0.099 $ 0.013 $ -

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2016
Stockholders Equity Note [Abstract]
Summary of All Outstanding Warrants to Purchase Shares of Common Stock	Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of September 30, 2016: Description Grant Date Warrants Issued Exercise Weighted Average Expiration Exercised Warrants 2012 Series A 11/26/2012 17,966,139 $ 1.1786 $ 1.1786 11/26/2017 - 17,966,139 2012 Placement 11/26/2012 261,250 $ 2.6400 $ 2.6400 11/26/2017 - 261,250 2012 Series A 12/18/2012 3,043,423 $ 1.1786 $ 1.1786 12/18/2017 - 3,043,423 2012 Placement 12/18/2012 22,500 $ 2.6400 $ 2.6400 12/18/2017 - 22,500 2013 Series C 10/29/2013 4,455,231 $ 0.0100 $ 0.0100 10/29/2018 - 4,455,231 2013 Series D 10/29/2013 28,369,815 $ 1.8144 $ 1.8144 10/29/2018 - 28,369,815 2013 Placement 10/29/2013 65,650 $ 2.6400 $ 2.6400 10/29/2018 - 65,650 2016 Series F 08/15/2016 3,143,208 $ 0.4375 $ 0.4375 08/15/2021 - 3,143,208 57,327,216 $ 1.37 - 57,327,216

STOCK BASED COMPENSATION (Table

STOCK BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Stock-Based Compensation Costs	Stock-based compensation costs under the Company’s equity incentive plans for the three and nine month periods ended September 30, 2016 and 2015 are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Research and development $ 220,960 $ 275,429 $ 703,324 $ 830,180 General and administrative 804,487 658,900 2,243,488 2,027,109 Total $ 1,025,447 $ 934,329 $ 2,946,812 $ 2,857,289
Schedule of Share-based Compensation, Activity	The Company issued the following stock options during the three and nine month periods ended September 30, 2016 and 2015, respectively: Three Months Ended Nine Months Ended 2016 2015 2016 2015 Stock Options - - 2,459,799 - Contingent Options - - 1,621,106 - Total granted - - 4,080,905 -
Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model and Monte Carlo Simulation Model	The Company estimated the fair value of the stock options granted using the Black-Scholes option-pricing model. The Company estimated the fair value of the Market Options granted using the Monte Carlo simulation model. The following key assumptions were used for both option grants for the nine months ended September 30, 2016 as no options were granted in the three months ended September 30, 2016 and the three and nine months ended September 30, 2015: Three Months Ended Nine Months Ended 2016 2015 2016 2015 Expected volatility N/A N/A 82% - 85% N/A Expected term N/A N/A 6 years N/A Dividend yield N/A N/A 0.0% N/A Risk- free interest rate N/A N/A 1.14% - 1.55% N/A Stock price N/A N/A $0.30 - $0.37 N/A Forfeiture rate N/A N/A 0.0% N/A
Summary of Status of Options Issued And Changes in Options Outstanding	Number of Weighted- Aggregate Options outstanding at December 31, 2015 7,027,658 $ 2.57 $ 7,824 Granted 4,080,905 0.37 414,296 Exercised - - - Cancelled (97,757) 2.23 - Options outstanding at September 30, 2016 11,010,806 $ 1.76 $ 422,120 Options vested and expected to vest at September 30, 2016 11,010,806 $ 1.76 $ 422,120 Exercisable at September 30, 2016 6,658,434 $ 2.53 $ 30,677 Shares available for grant under the 2016 Plan 5,007,743
Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding at September 30, 2016: Outstanding Exercisable Exercise Price Number of Weighted- Weighted- Number Weighted- $ 0.30 88,648 9.28 $ 0.30 19,699 $ 0.30 $ 0.36 48,399 9.09 $ 0.36 13,444 $ 0.36 $ 0.37 4,017,257 9.52 $ 0.37 258,496 $ 0.37 $ 0.85 136,785 8.09 $ 0.85 79,791 $ 0.85 $ 1.30 100,000 8.02 $ 1.30 59,375 $ 1.30 $ 2.40 5,097,075 6.46 $ 2.40 4,852,574 $ 2.40 $ 2.90 1,420,259 7.32 $ 2.90 1,272,672 $ 2.90 $ 8.00 65,000 3.82 $ 8.00 65,000 $ 8.00 $ 19.38 37,383 1.53 $ 19.38 37,383 $ 19.38 Total 11,010,806 7.72 $ 1.76 6,658,434 $ 2.53

Description of Business - Addit

Description of Business - Additional Information (Detail)	Sep. 30, 2016
Organization and Nature of Operations [Line Items]
Percentage of outstanding common stock collectively held by former stockholders of Old Arno	95.00%

Basis of Presentation and Sum25

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit	$ (102,995,403)	$ (93,294,953)

Liquidity and Capital Resourc26

Liquidity and Capital Resources - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Working Capital Detail [Line Items]
Cash and cash equivalents	$ 2,124,079	$ 123,272	$ 66,988	$ 7,948,436
Proceeds from Issuance of Common Stock	5,206,999	$ 0
August 2016 Purchase Agreement [Member]
Working Capital Detail [Line Items]
Proceeds from Issuance of Common Stock	$ 3,000,000

Potentially Dilutive Securities

Potentially Dilutive Securities (Detail) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Potentially Dilutive Securities Included in Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	11,752,743	4,455,231
Warrants to purchase common stock
Potentially Dilutive Securities Included in Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	7,598,439	4,455,231
Options to purchase common stock
Potentially Dilutive Securities Included in Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	4,154,304	0

Basic and Diluted Income_(Los28

Basic and Diluted Income/(Loss) Per Share - Additional Information (Detail) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	56,585,279	30,707,113

Intangible Assets and Intelle29

Intangible Assets and Intellectual Property - Additional Information (Detail) - USD ($)	Apr. 01, 2014	Feb. 13, 2012	Jul. 31, 2015	Feb. 28, 2014	Jan. 31, 2014	Oct. 31, 2013	Sep. 30, 2016	Dec. 31, 2008
Finite-Lived Intangible Assets [Line Items]
Services agreement monthly payment	$ 50,000	$ 70,833
University of Minnesota
Finite-Lived Intangible Assets [Line Items]
Written notice period for termination of license agreement if breach is not cured				60 days
Prior written notice period for termination of license agreement by the company for any reason				90 days
Onapristone License Agreement
Finite-Lived Intangible Assets [Line Items]
Written notice period for termination of license agreement if breach is not cured		90 days
Onapristone License Agreement | Invivis Pharmaceuticals, Inc
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement		$ 500,000			$ 100,000	$ 150,000
Aggregate potential milestone payments		$ 15,100,000
License agreement termination date		Feb. 13, 2012
Prior written notice period for termination of license agreement by the company for any reason		90 days
Onapristone License Agreement | Invivis Pharmaceuticals, Inc | Next Milestone Payment
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement			$ 350,000
AR-12 and AR-42 License Agreements | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement								$ 450,000
Written notice period for termination of license agreement if breach is not cured								90 days
Prior written notice period for termination of license agreement by the company for any reason								90 days
License agreement expiration date								20 years
AR-12 License Agreement | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Aggregate potential milestone payments								$ 6,100,000
Potential milestone payments, due after market approval								5,000,000
AR-42 License Agreement | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Aggregate potential milestone payments								5,100,000
Potential milestone payments, due after market approval								$ 4,000,000
AR-67 License Agreement
Finite-Lived Intangible Assets [Line Items]
Proceeds from Sale of Other Assets							$ 500,000

Convertible Notes Payable - (Ad

Convertible Notes Payable - (Additional Information) (Detail) - USD ($)	Jan. 12, 2016	Oct. 21, 2015	Dec. 31, 2015
Convertible Long Term Notes Payable [Line Items]
Unamortized Debt Issuance Expense			$ 10,091
Convertible Notes Payable
Convertible Long Term Notes Payable [Line Items]
Potential Additional Equity Financing		$ 3,500,000
Debt Related Commitment Fees and Debt Issuance Costs		12,528
Convertible Note Payable, Face Amount		$ 2,100,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Debt Conversion, Converted Instrument, Amount		$ 2,100,000
Debt Instrument, Maturity Date		Oct. 21, 2016
Stock Purchase Agreement | Convertible Notes Payable
Convertible Long Term Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Conversion, Converted Instrument, Amount	$ 2,100,000
Debt Conversion, Converted Instrument, Shares Issued	6,081,858
Shares Issued, Price Per Share	$ 0.35
Unamortized Debt Issuance Expense	$ 10,091
Stock Purchase Agreement | Convertible Notes, Accrued Interest
Convertible Long Term Notes Payable [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 28,652

Fair Value Hierarchy for Liabil

Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Liabilities
Derivative Liabilities Noncurrent	$ 6,541,644	$ 4,750,687
Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	6,541,644	4,750,687
Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	2,079,948	1,753,969
Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	3,689	7,661
Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	4,454,068	2,985,512
Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	3,939	3,545
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	6,541,644	4,750,687
Significant Other Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	2,079,948	1,753,969
Significant Other Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	3,689	7,661
Significant Other Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	4,454,068	2,985,512
Significant Other Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	$ 3,939	$ 3,545

Summary of Changes in Fair Valu

Summary of Changes in Fair Value of Liabilities (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
2013 Series E
Total Warrant Liability
Balance	$ 0	$ 25,737
Total gains or losses:
Unrealized appreciation/(depreciation)		(25,737)
Balance	$ 0	0
Value per Warrant	$ 0
2013 Series D
Total Warrant Liability
Balance	$ 2,985,512	3,011,249
Total gains or losses:
Unrealized appreciation/(depreciation)	1,468,556	(25,737)
Balance	$ 4,454,068	2,985,512
Value per Warrant	$ 0.157
2013 Placement Agent
Total Warrant Liability
Balance	$ 3,545	18,907
Total gains or losses:
Unrealized appreciation/(depreciation)	394	(15,362)
Balance	$ 3,939	3,545
Value per Warrant	$ 0.06
2012 Series B
Total Warrant Liability
Balance	$ 0	12,381
Total gains or losses:
Unrealized appreciation/(depreciation)		(12,381)
Balance	$ 0	0
Value per Warrant	$ 0
2012 Series A
Total Warrant Liability
Balance	$ 1,753,969	3,507,938
Total gains or losses:
Unrealized appreciation/(depreciation)	325,979	(1,753,969)
Balance	$ 2,079,948	1,753,969
Value per Warrant	$ 0.099
2012 Placement Agent
Total Warrant Liability
Balance	$ 7,661	67,246
Total gains or losses:
Unrealized appreciation/(depreciation)	(3,972)	(59,585)
Balance	$ 3,689	7,661
Value per Warrant	$ 0.013
2010 Class B
Total Warrant Liability
Balance	$ 0	28,066
Total gains or losses:
Unrealized appreciation/(depreciation)		(28,066)
Balance	$ 0	0
Value per Warrant	$ 0
Warrant
Total Warrant Liability
Balance	$ 4,750,687	6,671,524
Total gains or losses:
Unrealized appreciation/(depreciation)	1,790,957	(1,920,837)
Balance	$ 6,541,644	$ 4,750,687
Value per Warrant	$ 0.132

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)

Nov. 04, 2016

Aug. 15, 2016

Jan. 12, 2016

Nov. 03, 2016

Oct. 04, 2016

Sep. 30, 2015

Jan. 31, 2015

Sep. 30, 2016

Dec. 31, 2013

Dec. 31, 2012

Aug. 30, 2016

Dec. 31, 2015

Dec. 31, 2010

Stockholders Equity Note [Line Items]

Common stock, shares issued

47,849,036

20,408,616

Common stock, shares outstanding

47,849,036

20,408,616

Derivative liabilities

$ 6,541,644

$ 4,750,687

Shares Of Common Stock Reserved For Issuance Upon The Exercise Of Outstanding Options And Warrants

68,338,022

Stock Issued During Period Shares New Issues

21,153,997

Proceeds from Common Stock Subscribed

$ 150,000

Sale of Stock, Consideration Receivable

675,250

6% Notes

Stockholders Equity Note [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

6.00%

Securities Purchase Agreement

Stockholders Equity Note [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.4375

Sale Of Stock Number Of Shares Authorized In Transaction

8,501,421

Sale of Stock, Price Per Share

$ 0.35

Sale of Stock, Number of Shares Issued in Transaction

6,286,423

Sale Of Stock Remaining Number Of Shares In Transaction

1,929,284

Sale of Stock, Consideration Received Per Transaction

$ 2,200,000

Warrant Expiration Terms

5 years

Sale of Stock, Consideration Receivable

$ 675,250

Stock Purchase Agreement

Stockholders Equity Note [Line Items]

Proceeds from the issuance of stock, warrants, or units

$ 7,400,000

Shares Issued, Price Per Share

$ 0.35

Debt Conversion, Converted Instrument, Amount

$ 2,128,652

Debt Conversion, Converted Instrument, Shares Issued

6,081,858

Subsequent Event

Stockholders Equity Note [Line Items]

Number of securities called by warrants

142,857

Stock Issued During Period Shares New Issues

285,714

Sale of Stock, Consideration Received Per Transaction

$ 100,000

Subsequent Event | Securities Purchase Agreement

Stockholders Equity Note [Line Items]

Sale of Stock, Number of Shares Issued in Transaction

1,214,999

Sale Of Stock Remaining Number Of Shares In Transaction

1,929,284

Sale of Stock, Consideration Received Per Transaction

$ 425,250

Sale of Stock, Number of Shares To Be Issued in Transaction

714,285

Sale of Stock, Consideration To Be Received Per Transaction

$ 250,000

Subsequent Event | Stock Purchase Agreement

Stockholders Equity Note [Line Items]

Sale of Stock, Number of Shares To Be Issued in Transaction

714,285

Sale of Stock, Consideration To Be Received Per Transaction

$ 250,000

Maxim Group Llc

Stockholders Equity Note [Line Items]

Common stock, shares issued

7,500

Number of securities called by warrants

283,750

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2.64

Derivative liabilities

$ 0

0

Placement Fee Paid

$ 1,035,000

Class A Warrants

Stockholders Equity Note [Line Items]

Number of securities called by warrants

152,740

Class Of Warrant Or Right Initial Exercise Price Of Warrants Or Rights

$ 8

Number Of Warrants Expired Unexercised

152,740

Class B Warrants

Stockholders Equity Note [Line Items]

Number of securities called by warrants

801,885

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 3.55

Derivative liabilities

0

Class Of Warrant Or Right Initial Exercise Price Of Warrants Or Rights

$ 9.20

Number Of Warrants Expired Unexercised

801,885

Series A Warrant

Stockholders Equity Note [Line Items]

Number of securities called by warrants

18,207,273

10,317,464

21,009,562

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 1.36

$ 2.40

$ 1.18

Potential Additional Equity Financing

$ 12,000,000

Series B Warrant

Stockholders Equity Note [Line Items]

Number of securities called by warrants

6,190,500

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2.40

Number Of Warrants Expired Unexercised

6,190,500

Series D Warrant

Stockholders Equity Note [Line Items]

Number of securities called by warrants

24,053,398

28,369,815

12,868,585

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2.14

$ 1.81

$ 4

Derivative liabilities

$ 4,500,000

3,000,000

Series E Warrant

Stockholders Equity Note [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

2.40

Number Of Warrants Expired Unexercised

12,868,585

Series F Warrant

Stockholders Equity Note [Line Items]

Number of securities called by warrants

3,145,208

Class Of Warrant Or Right Initial Exercise Price Of Warrants Or Rights

$ 0.4375

Class Of Warrant Or Rights, Warrant Expiration Term

5 years

Securities Purchase and Registration Rights Agreement | Series C Warrant

Stockholders Equity Note [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.01

Series A and B Warrants

Stockholders Equity Note [Line Items]

Derivative liabilities

$ 2,100,000

$ 1,800,000

Summary of All Outstanding Warr

Summary of All Outstanding Warrants to Purchase Shares of Common Stock (Detail)	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Warrant 1
Class of Warrant or Right [Line Items]
Grant Date	Nov. 26, 2012
Warrants Issued	17,966,139
Exercise Price | $ / shares	$ 1.1786
Weighted Average Exercise Price | $ / shares	$ 1.1786
Expiration Date	Nov. 26, 2017
Exercised	0
Warrants Outstanding	17,966,139
Warrant 2
Class of Warrant or Right [Line Items]
Grant Date	Nov. 26, 2012
Warrants Issued	261,250
Exercise Price | $ / shares	$ 2.6400
Weighted Average Exercise Price | $ / shares	$ 2.6400
Expiration Date	Nov. 26, 2017
Exercised	0
Warrants Outstanding	261,250
Warrant 3
Class of Warrant or Right [Line Items]
Grant Date	Dec. 18, 2012
Warrants Issued	3,043,423
Exercise Price | $ / shares	$ 1.1786
Weighted Average Exercise Price | $ / shares	$ 1.1786
Expiration Date	Dec. 18, 2017
Exercised	0
Warrants Outstanding	3,043,423
Warrant 4
Class of Warrant or Right [Line Items]
Grant Date	Dec. 18, 2012
Warrants Issued	22,500
Exercise Price | $ / shares	$ 2.6400
Weighted Average Exercise Price | $ / shares	$ 2.6400
Expiration Date	Dec. 18, 2017
Exercised	0
Warrants Outstanding	22,500
Warrant 5
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	4,455,231
Exercise Price | $ / shares	$ 0.0100
Weighted Average Exercise Price | $ / shares	$ 0.0100
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	4,455,231
Warrant 6
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	28,369,815
Exercise Price | $ / shares	$ 1.8144
Weighted Average Exercise Price | $ / shares	$ 1.8144
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	28,369,815
Warrant 7
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	65,650
Exercise Price | $ / shares	$ 2.6400
Weighted Average Exercise Price | $ / shares	$ 2.6400
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	65,650
Warrant 8
Class of Warrant or Right [Line Items]
Grant Date	Aug. 15, 2016
Warrants Issued	3,143,208
Exercise Price | $ / shares	$ 0.4375
Weighted Average Exercise Price | $ / shares	$ 0.4375
Expiration Date	Aug. 15, 2021
Exercised	0
Warrants Outstanding	3,143,208
Total Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants Issued	57,327,216
Weighted Average Exercise Price | $ / shares	$ 1.37
Exercised	0
Warrants Outstanding	57,327,216

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 14, 2016	Oct. 07, 2013	Jan. 14, 2013	Apr. 25, 2011	Jun. 03, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of stock options granted (in years)			7 years 8 months 19 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 952,576	$ 935,446	$ 2,802,664	$ 3,590,708
Total unrecognized estimated compensation cost related to stock options	$ 1,784,552		$ 1,784,552
Total unrecognized estimated compensation cost related to stock options, recognition period			2 years 6 months
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number	11,010,806		11,010,806
Market option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of stock options granted (in years)			10 years
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of stock options granted (in years)			10 years
2005 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance							11,155,295	945,276	875,000	373,831
Term of stock options granted (in years)			10 years
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number					7,018,549
2005 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years
2005 Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			3 years
2016 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance	5,007,743		5,007,743			9,000,000
Term of stock options granted (in years)			10 years
Share-based Compensation Arrangement by Share-based Payment Award Maximum Number Of Shares Issuable	4,000,000		4,000,000
2016 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			4 years
2016 Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			3 years

Stock-Based Compensation Costs

Stock-Based Compensation Costs (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$ 1,025,447	$ 934,329	$ 2,946,812	$ 2,857,289
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	220,960	275,429	703,324	830,180
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$ 804,487	$ 658,900	$ 2,243,488	$ 2,027,109

Options Granted (Detail)

Options Granted (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted	0	0	4,080,905	0
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted	0	0	2,459,799	0
Contingent Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted	0	0	1,621,106	0

Assumptions Used in Estimating

Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model and Monte Carlo Simulation Model (Detail)	9 Months Ended
	Sep. 30, 2016$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years
Dividend yield	0.00%
Forfeiture rate	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	82.00%
Risk- free interest rate	1.14%
Stock price	$ 0.30
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	85.00%
Risk- free interest rate	1.55%
Stock price	$ 0.37

Summary of Status of Options Is

Summary of Status of Options Issued and Changes in Options Outstanding (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Number of Shares
Options Granted	0	0	4,080,905	0
Ending Balance	11,010,806		11,010,806
Exercisable	6,658,434		6,658,434
Weighted-Average Exercise Price
Ending Balance	$ 1.76		$ 1.76
Exercisable	$ 2.53		$ 2.53
Equity Incentive Plans
Number of Shares
Beginning Balance			7,027,658
Options Granted			4,080,905
Options Exercised			0
Options Cancelled			(97,757)
Ending Balance	11,010,806		11,010,806
Options vested and expected to vest			11,010,806
Exercisable	6,658,434		6,658,434
Shares available for grant under the 2016 Plan	5,007,743		5,007,743
Weighted-Average Exercise Price
Beginning Balance			$ 2.57
Options Granted			0.37
Options Exercised			0
Options Cancelled			2.23
Ending Balance	$ 1.76		1.76
Options vested and expected to vest	1.76		1.76
Exercisable	$ 2.53		$ 2.53
Aggregate Intrinsic Value
Beginning Balance			$ 7,824
Options Granted			414,296
Options Exercised			0
Options Cancelled			0
Ending Balance	$ 422,120		422,120
Options vested and expected	422,120		422,120
Exercisable	$ 30,677		$ 30,677

Summary of Information about St

Summary of Information about Stock Options Outstanding (Detail)	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	11,010,806
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	7 years 8 months 19 days
Options Outstanding, Weighted-Average Exercise Price	$ 1.76
Options Exercisable, Shares | shares	6,658,434
Options Exercisable, Weighted- Average Exercise Price	$ 2.53
Exercise Price 0.30
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 0.30
Options Outstanding, Shares | shares	88,648
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 3 months 11 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.30
Options Exercisable, Shares | shares	19,699
Options Exercisable, Weighted- Average Exercise Price	$ 0.30
Exercise Price 0.36
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 0.36
Options Outstanding, Shares | shares	48,399
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 1 month 2 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.36
Options Exercisable, Shares | shares	13,444
Options Exercisable, Weighted- Average Exercise Price	$ 0.36
Exercise Price 0.37
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 0.37
Options Outstanding, Shares | shares	4,017,257
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 6 months 7 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.37
Options Exercisable, Shares | shares	258,496
Options Exercisable, Weighted- Average Exercise Price	$ 0.37
Exercise Price 0.85
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 0.85
Options Outstanding, Shares | shares	136,785
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	8 years 1 month 2 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.85
Options Exercisable, Shares | shares	79,791
Options Exercisable, Weighted- Average Exercise Price	$ 0.85
Exercise Price 1.30
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 1.30
Options Outstanding, Shares | shares	100,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	8 years 7 days
Options Outstanding, Weighted-Average Exercise Price	$ 1.30
Options Exercisable, Shares | shares	59,375
Options Exercisable, Weighted- Average Exercise Price	$ 1.30
Exercise Price 2.40
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 2.40
Options Outstanding, Shares | shares	5,097,075
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	6 years 5 months 16 days
Options Outstanding, Weighted-Average Exercise Price	$ 2.40
Options Exercisable, Shares | shares	4,852,574
Options Exercisable, Weighted- Average Exercise Price	$ 2.40
Exercise Price 2.90
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 2.90
Options Outstanding, Shares | shares	1,420,259
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	7 years 3 months 25 days
Options Outstanding, Weighted-Average Exercise Price	$ 2.90
Options Exercisable, Shares | shares	1,272,672
Options Exercisable, Weighted- Average Exercise Price	$ 2.90
Exercise price 8.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 8
Options Outstanding, Shares | shares	65,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	3 years 9 months 25 days
Options Outstanding, Weighted-Average Exercise Price	$ 8
Options Exercisable, Shares | shares	65,000
Options Exercisable, Weighted- Average Exercise Price	$ 8
Exercise price 19.38
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 19.38
Options Outstanding, Shares | shares	37,383
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	1 year 6 months 11 days
Options Outstanding, Weighted-Average Exercise Price	$ 19.38
Options Exercisable, Shares | shares	37,383
Options Exercisable, Weighted- Average Exercise Price	$ 19.38

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - USD ($)	Nov. 04, 2016	Aug. 15, 2016	Jan. 12, 2016	Nov. 03, 2016	Oct. 04, 2016	Sep. 30, 2016
Subsequent Event [Line Items]
Stock Issued During Period Shares New Issues			21,153,997
Sale of Stock, Consideration Receivable						$ 675,250
Securities Purchase Agreement
Subsequent Event [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		6,286,423
Warrant Expiration Terms		5 years
Sale of Stock, Consideration Received Per Transaction		$ 2,200,000
Sale Of Stock Remaining Number Of Shares In Transaction		1,929,284
Sale of Stock, Consideration Receivable		$ 675,250
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period Shares New Issues					285,714
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights					142,857
Sale of Stock, Consideration Received Per Transaction					$ 100,000
Subsequent Event [Member] | Securities Purchase Agreement
Subsequent Event [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	1,214,999
Sale of Stock, Consideration Received Per Transaction	$ 425,250
Sale Of Stock Remaining Number Of Shares In Transaction				1,929,284
Sale of Stock, Number of Shares To Be Issued in Transaction	714,285
Sale of Stock, Consideration To Be Received Per Transaction	$ 250,000